# US 12,622,974 B2 · Siderophore-dihydrofolate reductase inhibitor conjugate and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,622,974 B2
- Document ID: US12622974B2
- Status: Granted
- Kind: B2
- Application number: 17/720,192
- Filed: 2022-04-13
- Published: 2022-08-04
- Granted: 2026-05-12
- Earliest claimed: 2020-01-23
- Assignees: Jasan Bio Medicine (Jiaxing) Co., Ltd
- Applicants: Jasan Bio Medicine (Jiaxing) Co., Ltd
- Inventors: Yun He; Yan Guan
- Web page: https://patentgrep.com/patent/US12622974B2

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/552: {one of the codrug's components being an antibiotic}
- A61P 31/04: Antibacterial agents
- C07D 487/04: Ortho-condensed systems
- C07K 5/0606: {the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr}
- C07K 5/081: {the side chain containing O or S as heteroatoms, e.g. Cys, Ser}
- C07K 5/1013: {the side chain containing O or S as heteroatoms, e.g. Cys, Ser}
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A conjugate provided. The conjugate is a compound represented by Formula (I), or the conjugate is a stereoisomer, tautomer, homologue, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the compound represented by Formula (I): where A is a linker, and B is a dihydrofolate reductase inhibitor; R1, R2, R3, R4, and R5 are independently selected from H or C1-6 alkyl; and n1, n2, and n3 are each an integer selected from 0 to 6.

## Claims

### Claim 1

A conjugate, being a compound represented by Formula (I), or being a stereoisomer, tautomer, homologue, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (I):
wherein A is a linker selected from heteroatom-containing alkane, amino acid, or amide, and B is a dihydrofolate reductase inhibitor, the dihydrofolate reductase inhibitor being methotrexate;
R1, R2, R3, R4, and R5 are independently selected from H or C1-6 alkyl; and
n1, n2, and n3 are each an integer selected from 1 to 3.

### Claim 2 (depends on 1)

The conjugate according to claim 1, wherein the conjugate is any one of the following compounds, or a stereoisomer, tautomer, homologue, solvate, or pharmaceutically acceptable salt of any one of the following compounds:

### Claim 3 (depends on 1)

A pharmaceutical composition comprising the conjugate according to claim 1 and a pharmaceutically acceptable excipient,
wherein the conjugate is a compound represented by Formula (I), or is a stereoisomer, tautomer, homologue, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (I):
wherein A is a linker selected from heteroatom-containing alkane, amino acid, or amide, and B is a dihydrofolate reductase inhibitor, the dihydrofolate reductase inhibitor being methotrexate;
R1, R2, R3, R4, and R5 are independently selected from H or C1-6 alkyl; and
n1, n2, and n3 are each an integer selected from 1 to 3.
